114 related articles for article (PubMed ID: 8260241)
1. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome.
Montes A; Powles TJ; O'Brien ME; Ashley SE; Luckit J; Treleaven J
Eur J Cancer; 1993; 29A(13):1854-7. PubMed ID: 8260241
[TBL] [Abstract][Full Text] [Related]
2. Haemolytic uraemic syndrome in a patient with lung cancer: further evidence for a toxic interaction between mitomycin-C and tamoxifen.
Ellis PA; Luckitt J; Treleaven J; Smith IE
Clin Oncol (R Coll Radiol); 1996; 8(6):402-3. PubMed ID: 8973862
[No Abstract] [Full Text] [Related]
3. Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial.
Stein RC; Bower M; Law M; Bliss JM; Barton C; Gazet JC; Ford HT; Coombes RC
Eur J Cancer; 1992; 28A(12):1963-5. PubMed ID: 1419290
[TBL] [Abstract][Full Text] [Related]
4. Use of erythropoietin in the management of the haemolytic uraemic syndrome induced by mitomycin C/tamoxifen.
O'Brien ME; Casey S; Treleaven J; Powles TJ
Eur J Cancer; 1994; 30A(6):894-5. PubMed ID: 7917560
[No Abstract] [Full Text] [Related]
5. [Three cases of drug-induced hemolytic uremic syndrome].
Tohda S; Shiigai T; Jibiki M; Aoi T; Ueda Y; Kawasaki T; Kurokawa H; Nara N
Gan To Kagaku Ryoho; 1996 Feb; 23(3):361-4. PubMed ID: 8712831
[TBL] [Abstract][Full Text] [Related]
6. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.
Powles TJ; Jones AL; Judson IR; Hardy JR; Ashley SE
Br J Cancer; 1991 Aug; 64(2):406-10. PubMed ID: 1892775
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone, mitomycin-C, methotrexate combination chemotherapy with radiotherapy and/or surgery in stage III (T4B, NO-2, M0) breast cancer.
Raina V; Sharma A; Deo SV; Shukla NK; Mohanty BK; Goel A; Rath GK
J Assoc Physicians India; 1998 Nov; 46(11):926-9. PubMed ID: 11229215
[TBL] [Abstract][Full Text] [Related]
8. Haemolytic uraemic syndrome associated with gemcitabine.
Moya-Horno I; Querol Niñerola R; Bonfill Abella T; Dalmau Pórtulas E; Gallardo-Díaz E; Saigí Grau E; Pericay Pijaume C
Clin Transl Oncol; 2010 May; 12(5):381-3. PubMed ID: 20466623
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer.
O'Brien ME; Nicolson M; Montes A; Tidy A; Ashley S; Powles TJ
Br J Cancer; 1994 Nov; 70(5):980-3. PubMed ID: 7524607
[TBL] [Abstract][Full Text] [Related]
10. Mitomycin C-related hemolytic uremic syndrome in cancer patients.
Schiebe ME; Hoffmann W; Belka C; Bamberg M
Anticancer Drugs; 1998 Jun; 9(5):433-5. PubMed ID: 9660541
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy-induced hemolytic uremic syndrome. A complication to mitomycin treatment of breast carcinoma].
Schjølseth SA; Hagen T; Ottestad L; Jakobsen E
Tidsskr Nor Laegeforen; 1995 Nov; 115(27):3371-3. PubMed ID: 7491579
[TBL] [Abstract][Full Text] [Related]
12. [Hemolytic uremic syndrome--a serious complication of mitomycin treatment].
Arola O; Aho H; Asola M; Kauppila M; Nikkanen V; Voipio-Pulkki LM
Duodecim; 1997; 113(19):1923-9. PubMed ID: 10892085
[No Abstract] [Full Text] [Related]
13. [Chemotherapy-associated hemolytic uremic syndrome--a case report].
Kikuchi H; Kanamaru R
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1927-9. PubMed ID: 1519930
[TBL] [Abstract][Full Text] [Related]
14. Mitomycin C associated hemolytic uremic syndrome.
Jain S; Seymour AE
Pathology; 1987 Jan; 19(1):58-61. PubMed ID: 3108839
[TBL] [Abstract][Full Text] [Related]
15. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
Jodrell DI; Smith IE; Mansi JL; Pearson MC; Walsh G; Ashley S; Sinnett HD; McKinna JA
Br J Cancer; 1991 May; 63(5):794-8. PubMed ID: 2039705
[TBL] [Abstract][Full Text] [Related]
16. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.
Cantrell JE; Phillips TM; Schein PS
J Clin Oncol; 1985 May; 3(5):723-34. PubMed ID: 3923162
[TBL] [Abstract][Full Text] [Related]
17. Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report.
Serke S; Riess H; Oettle H; Huhn D
Br J Cancer; 1999 Mar; 79(9-10):1519-21. PubMed ID: 10188900
[TBL] [Abstract][Full Text] [Related]
18. [Mitomycin-induced hemolytic-uremic syndrome].
Zeller G; Wandel E; Schwarting A
Dtsch Med Wochenschr; 2003 Jun; 128(25-26):1399-402. PubMed ID: 12813674
[TBL] [Abstract][Full Text] [Related]
19. Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era.
El-Ghazal R; Podoltsev N; Marks P; Chu E; Saif MW
Clin Colorectal Cancer; 2011 Jun; 10(2):142-5. PubMed ID: 21859568
[TBL] [Abstract][Full Text] [Related]
20. Myelosuppression after methotrexate, mitozantrone, and mitomycin C for treatment of advanced breast cancer.
Marks A; Goodman A; Dougherty S; Ashford R
Lancet; 1987 Apr; 1(8538):915. PubMed ID: 2882308
[No Abstract] [Full Text] [Related]
[Next] [New Search]
